Document 1131
 DOCN  M94A1131
 TI    Survival trends of patients infected with HIV treated with zidovudine
       (Retrovir). Experience from a private practice group in Venezuela.
 DT    9412
 AU    Rodriguez-Adrian L; Comegna M; Guzman M; Isturiz M; Murillo J; Hospital
       Privado Centro Medico de Caracas, Venezuela.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(2):201 (abstract no. PB0817). Unique
       Identifier : AIDSLINE ICA10/94371444
 AB    OBJECTIVE: Evaluate survival of patients infected with HIV
       (asymptomatic, ARC and AIDS) treated with Zidovudine and followed by a
       private practice group between 1985 and 1993. METHODS: We
       retrospectively reviewed 321 charts of patients infected with HIV
       infection. Seventy nine fulfilled the following criteria: CD4
       lymphocytes less than 500 cell/ml, treatment for six months or longer,
       dosage equal or greater than 300 mg/day, and follow up of no less than
       12 months. Median and cumulative probability of survival were calculated
       using Kaplan-Meier techniques. RESULTS: Overall survival of 17
       asymptomatic treated patients was 100% at 68 months. For 23 patients
       with ARC the probability of survival was 90% at 1 year and 55% at 5
       years. The median survival for 39 patients with AIDS was 31 months, and
       the probability of survival for the same patients was 89% at 1 year and
       23% at 5 years. DISCUSSION AND CONCLUSIONS: 1. Compared to historical
       untreated controls, our patients survived longer and the survival was
       similar to that reported in the world literature, for the Zidovudine
       treated patients. 2. Treatment with Zidovudine appears useful for
       patients infected with HIV in our country. 3. The lowest effective dose
       of Zidovudine should be evaluated prospectively in our patient
       population.
 DE    Human  HIV Infections/*DRUG THERAPY/MORTALITY  Retrospective Studies
       Survival Rate  Time Factors  Zidovudine/*THERAPEUTIC USE  MEETING
       ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).